Log in

Relevant bibliographies by topics / The history of Cancer / Journal articles

To see the other types of publications on this topic, follow the link: The history of Cancer.

Journal articles on the topic 'The history of Cancer'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'The history of Cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Li, Xinjun, Anni I. Koskinen, Otto Hemminki, et al. "Family History of Head and Neck Cancers." Cancers 13, no. 16 (2021): 4115. http://dx.doi.org/10.3390/cancers13164115.

Full text

Abstract:

Background: Head and neck cancers (HNCs) encompass a heterogeneous group of cancers between the mouth and larynx. Familial clustering in HNCs has been described, but how it influences individual sites and to which extent known risk factors, such as human papilloma virus (HPV) infection, may contribute is not well established. Patients/methods: We employed standardized incidence ratios (SIRs) to estimate familial risks for HNC with same (concordant) and different (discordant) cancers among first-degree relatives using data from the Swedish Cancer Registry from 1958 to 2018. Results: Incidence f

APA, Harvard, Vancouver, ISO, and other styles

2

Li, Xinjun, Anni I. Koskinen, Otto Hemminki, et al. "Family History of Head and Neck Cancers." Cancers 13, no. 16 (2021): 12. https://doi.org/10.3390/cancers13164115.

Full text

Abstract:

BACKGROUND: Head and neck cancers (HNCs) encompass a heterogeneous group of cancers between the mouth and larynx. Familial clustering in HNCs has been described, but how it influences individual sites and to which extent known risk factors, such as human papilloma virus (HPV) infection, may contribute is not well established. PATIENTS/METHODS: We employed standardized incidence ratios (SIRs) to estimate familial risks for HNC with same (concordant) and different (discordant) cancers among first-degree relatives using data from the Swedish Cancer Registry from 1958 to 2018. RESULTS: Incidence f

APA, Harvard, Vancouver, ISO, and other styles

3

Heath, John A., Elizabeth Smibert, Elizabeth M. Algar, Gillian S. Dite, and John L. Hopper. "Cancer Risks for Relatives of Children with Cancer." Journal of Cancer Epidemiology 2014 (2014): 1–4. http://dx.doi.org/10.1155/2014/806076.

Full text

Abstract:

We determined the extent and distribution of cancers in relatives of 379 children newly diagnosed with cancer. Family history was collected from 1,337 first-degree and 3,399 second-degree relatives and incidence compared with national age- and gender-specific rates. Overall, 14 children (3.7%) had a relative with a history of childhood cancer and 26 children (6.9%) had a first-degree relative with a history of cancer, with only one of these having an identifiable familial cancer syndrome. There was a higher than expected incidence of childhood cancer among first-degree relatives (parents and s

APA, Harvard, Vancouver, ISO, and other styles

4

Artanto, Kurniawan Ros, and Sujono Riyadi. "Kanker Paru Berdasarkan Riwayat Paparan Rokok." Wiraraja Medika : Jurnal Kesehatan 14, no. 2 (2024): 55–60. https://doi.org/10.24929/fik.v14i2.3426.

Full text

Abstract:

Lung cancer is a condition whose exact cause is not yet known. There are various risk factors for lung cancer. However, a history of exposure to cigarettes is one of the main risk factors in lung cancer cases. The aim of the research was to understand the characteristics of lung cancer patients based on their history of exposure to cigarettes at Hospital on Yogyakarta in 2023. This research method is a Quantitative, descriptive; provides an overview of the characteristics of lung cancer patients based on history of exposure to cigarettes. Univariate; characteristics of lung cancer patients bas

APA, Harvard, Vancouver, ISO, and other styles

5

Hemminki, Kari, Jan Sundquist, and Andreas Brandt. "Familial Mortality and Familial Incidence in Cancer." Journal of Clinical Oncology 29, no. 6 (2011): 712–18. http://dx.doi.org/10.1200/jco.2010.30.5664.

Full text

Abstract:

Purpose An overwhelming majority of data on familial risk in cancer is based on incident cancer, whereas familiality in cancer mortality is largely unknown. If fatal form of cancer was a highly familial subtype, then familial risk for mortality may exceed that of incidence, which would be particularly relevant for clinical decision making and counseling. Patients and Methods The individuals in the nationwide Swedish Family-Cancer Database were classified according to family history of fatal and nonfatal cancer. Familial risks of incident and fatal concordant cancer were calculated for offsprin

APA, Harvard, Vancouver, ISO, and other styles

6

Anderson, Kristin, Patricia Thompson, Betsy Wertheim, et al. "Family history and breast cancer subtype among women of Mexican descent." Journal of Clinical Oncology 32, no. 26_suppl (2014): 41. http://dx.doi.org/10.1200/jco.2014.32.26_suppl.41.

Full text

Abstract:

41 Background: A family history of breast cancer in a first-degree relative is associated with a 2-fold increase in breast cancer risk; however, breast cancer is a heterogeneous disease and there may be differences in risk profiles driven by tumor subtype or by racial/ethnic group. Methods: We assessed prevalence of familial breast cancer and its association with tumor subtype among 914 women with breast cancer of Mexican descent enrolled in the Ella Study, a case-only, binational (U.S.-Mexico) breast cancer study. Logistic regression was conducted to compare odds of triple negative breast can

APA, Harvard, Vancouver, ISO, and other styles

7

Clift, Kristin, Sarah Macklin-Mantia, Margaret Barnhorst, et al. "Comparison of a Focused Family Cancer History Questionnaire to Family History Documentation in the Electronic Medical Record." Journal of Primary Care & Community Health 13 (January 2022): 215013192110697. http://dx.doi.org/10.1177/21501319211069756.

Full text

Abstract:

Introduction: Family health history can be a valuable indicator of risk to develop certain cancers. Unfortunately, patient self-reported family history often contains inaccuracies, which might change recommendations for cancer screening. We endeavored to understand the difference between a patient’s self-reported family history and their electronic medical record (EMR) family history. One aim of this study was to determine if family history information contained in the EMR differs from patient-reported family history collected using a focused questionnaire. Methods: We created the Hereditary C

APA, Harvard, Vancouver, ISO, and other styles

8

Abduloeva, N. K., M. V. Scriabin, О. А. Skripko, et al. "HISTORY OF CANCER HORMONOTHERAPY." Practical oncology 24, no. 2 (2023): 105–18. http://dx.doi.org/10.31917/2402105.

Full text

Abstract:

breast cancer, epidemiology, risk factors, classification, diagnosis, prognosis, marker, treatment, Lobular carcinoma in situ ((DCIS), time to progression (TTP), complete regression, partial regression, metastatic breast cancer (MBC), median progression-free survival (PFS), overall response, LH-RH agonists and antagonists, receptor estrogen, LH-releasing hormone, Gonadotropin-releasing-hormone-receptor antagonists, overall survival, prostate cancer, Castration-resistant prostate cancer (CRPC), receptor androgens, prostate-specific antigen (PSA)

APA, Harvard, Vancouver, ISO, and other styles

9

Earle, Craig. "Sensitivity and specificity of self-reported cancer history compared to cancer registry." Journal of Clinical Oncology 35, no. 8_suppl (2017): 234. http://dx.doi.org/10.1200/jco.2017.35.8_suppl.234.

Full text

Abstract:

234 Background: The Ontario Health Study (OHS) is a large prospective epidemiologic cohort study in which any Ontario resident eighteen years of older may enroll regardless of prior medical history. Baseline data are collected using web-based tools. As part of the consent process, participants are asked for consent to link study data with administrative and health care claims databases, including the Ontario Cancer Registry (OCR). There is an option to enter their Health Insurance Number (HIN) for this purpose. The purpose of this study was to link these data and evaluate the accuracy of self-

APA, Harvard, Vancouver, ISO, and other styles

10

Suzuki, J., T. Hojo, K. Jimbo, S. Asaga, and T. Kinoshita. "Risk of breast cancer among Japanese women with a positive family history." Journal of Clinical Oncology 29, no. 27_suppl (2011): 191. http://dx.doi.org/10.1200/jco.2011.29.27_suppl.191.

Full text

Abstract:

191 Background: Most breast cancer cases are sporadic, rather than associated with inherited gene mutations, such as BRCA1 and BRCA2. However, women with a family history of breast cancer are at increased risk of developing breast cancer compared to those women without any family history, even if they lack these gene mutations. Methods: We analyzed 10892 patients including bilateral breast cancer cases (total of 11398 breast cancers) who underwent surgery at our hospital between 1962 and 2009. We excluded 295 cases whose family history data were not available. Clinical and pathological differe

APA, Harvard, Vancouver, ISO, and other styles

11

Sledge, George W. "History, Politics & Cancer." Oncology Times 39, no. 18 (2017): 20–21. http://dx.doi.org/10.1097/01.cot.0000525703.79616.8a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Scholz, A. "History of skin cancer." Melanoma Research 6, SUPPLEMENT 1 (1996): S27. http://dx.doi.org/10.1097/00008390-199609001-00068.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

LYNCH, HENRY T., RAMON M. FUSARO, and JANE F. LYNCH. "Family History of Cancer." Annals of the New York Academy of Sciences 768, no. 1 (1995): 12–29. http://dx.doi.org/10.1111/j.1749-6632.1995.tb12105.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Orom, Heather, Michele L. Coté, Hector M. González, Willie Underwood, and Ann G. Schwartz. "Family history of cancer." Cancer 112, no. 2 (2008): 399–406. http://dx.doi.org/10.1002/cncr.23173.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Sanginov, J. R., M. Mahmad, M. Kh Naibov, R. A. Zoirov, and N. A. Safarzoda. "CLINICAL CASE OF A BURDENED FAMILY HISTORY OF COLORECTAL CANCER." SCIENCE AND EDUCATION 1, no. 3 (2024): 289–300. https://doi.org/10.25005/3078-5022-2024-1-3-289-300.

Full text

Abstract:

Familial colorectal cancer constitutes a heterogeneous group of patients. Between 2% to 5% of all colon cancers arise in the setting of well–defined inherited syndromes, including Lynch syndrome, familial adenomatous polyposis. Each is associated with a high risk of colon cancer. In addition to the syndromes, up to one–third of colon cancers exhibit increased familial risk, likely related to inheritance. A number of less penetrant, but possibly more frequent susceptibility genes have been identified for this level of inheritance. Clarification of predisposing genes allows for accurate risk ass

APA, Harvard, Vancouver, ISO, and other styles

16

LaDuca, Holly, Rachel McFarland, Stephanie Gutierrez, et al. "Quality of Clinician-Reported Cancer History When Ordering Genetic Testing." JCO Clinical Cancer Informatics, no. 2 (December 2018): 1–11. http://dx.doi.org/10.1200/cci.18.00014.

Full text

Abstract:

Purpose Clinical history data reported on test requisition forms (TRFs) for hereditary cancer multigene panel testing (MGPT) are routinely used by genetic testing laboratories. More recently, publications have incorporated TRF-based clinical data into studies exploring yield of testing by phenotype and estimating cancer risks for mutation carriers. We aimed to assess the quality of TRF data for patients undergoing MGPT. Patients and Methods Ten percent of patients who underwent hereditary cancer MGPT between January and June 2015 at a clinical laboratory were randomly selected. TRF-reported ca

APA, Harvard, Vancouver, ISO, and other styles

17

Shi, Chanjuan, Ralph H. Hruban, and Alison P. Klein. "Familial Pancreatic Cancer." Archives of Pathology & Laboratory Medicine 133, no. 3 (2009): 365–74. http://dx.doi.org/10.5858/133.3.365.

Full text

Abstract:

Abstract Context.—Approximately 5% to 10% of individuals with pancreatic cancer report a history of pancreatic cancer in a close family member. In addition, several known genetic syndromes, such as familial breast cancer (BRCA2), the Peutz-Jeghers syndrome, and the familial atypical multiple mole melanoma syndrome, have been shown to be associated with an increased risk of pancreatic cancer. The known genes associated with these conditions can explain only a portion of the clustering of pancreatic cancer in families, and research to identify additional susceptibility genes is ongoing. Objectiv

APA, Harvard, Vancouver, ISO, and other styles

18

Kurian, Allison W., Paul Abrahamse, Kevin C. Ward, et al. "Association of Family Cancer History With Pathogenic Variants in Specific Breast Cancer Susceptibility Genes." JCO Precision Oncology, no. 5 (November 2021): 1853–59. http://dx.doi.org/10.1200/po.21.00261.

Full text

Abstract:

PURPOSE Family cancer history is an important component of genetic testing guidelines that estimate which patients with breast cancer are most likely to carry a germline pathogenic variant (PV). However, we do not know whether more extensive family history is differentially associated with PVs in specific genes. METHODS All women diagnosed with breast cancer in 2013-2017 and reported to statewide SEER registries of Georgia and California were linked to clinical genetic testing results and family history from two laboratories. Family history was defined as strong (suggestive of PVs in high-pene

APA, Harvard, Vancouver, ISO, and other styles

19

Liu, Jiaqing, Huaqiang Zhou, Yaxiong Zhang, et al. "Impact of prior cancer history on the overall survival of younger patients with lung cancer." ESMO Open 5, no. 1 (2020): e000608. http://dx.doi.org/10.1136/esmoopen-2019-000608.

Full text

Abstract:

BackgroundPatients with a history of prior cancer are frequently excluded from cancer trials. Previous studies indicated that prior cancer does not adversely impact clinical outcomes for patients with lung cancer older than 65 years. However, it remains unknown whether these results are applicable to patients with lung cancer aged younger than 65 years old. The study aimed to investigate the impact of prior cancer history on younger patients with lung cancer.MethodsWe identified younger patients with lung cancer (<65 years) diagnosed between 2004 and 2009 in the Surveillance, Epidemiology,

APA, Harvard, Vancouver, ISO, and other styles

20

Previs, Rebecca A., Heidi Chwan Ko, Zachary D. Wallen, et al. "Real-world clinical and genomic analysis of patients with a personal or family history of cancer undergoing germline testing for BRCA1 and BRCA2." Journal of Clinical Oncology 41, no. 16_suppl (2023): e22538-e22538. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e22538.

Full text

Abstract:

e22538 Background: Germline genetic testing for hereditary cancer syndromes is essential to the management of patients with cancer, providing information with both therapeutic implications and guidance for preventative strategies for patients and at-risk family members. BRCA1 and BRCA2 are the most common genes with deleterious mutations associated with increased risk of developing hereditary breast, ovarian, prostate and pancreatic cancers. The objective of this study was to explore the prevalence of germline BRCA1 and BRCA2 mutations in individuals with known cancer compared to those with on

APA, Harvard, Vancouver, ISO, and other styles

21

Yadav, Budhi Singh, Suresh C. Sharma, Firuza D. Patel, Bhavana Rai, and Sushmita Ghoshal. "Gynecological Cancer as a Second Malignancy in Patients With Breast Cancer." International Journal of Gynecologic Cancer 27, no. 6 (2017): 1298–304. http://dx.doi.org/10.1097/igc.0000000000000993.

Full text

Abstract:

PurposeThe aim of this study was to determine the incidence and risk factors for gynecological cancer as second malignancy (SM) after treatment of breast cancer (BC).Methods and MaterialsBetween January 1985 and December 2007, a total of 2756 patients with BC were analyzed for gynecological cancers as an SM. Analysis was carried out for patient-, disease-, and treatment-related characteristics. The Cox proportional hazards regression model was used to estimate the relative risk of gynecologic malignancies.ResultsThe median age at BC diagnosis was 49 years and median follow-up of 14 years. In t

APA, Harvard, Vancouver, ISO, and other styles

22

Sud, Amit, Hauke Thomsen, Kristina Sundquist, Richard S. Houlston, and Kari Hemminki. "Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History." Journal of Clinical Oncology 35, no. 14 (2017): 1584–90. http://dx.doi.org/10.1200/jco.2016.70.9709.

Full text

Abstract:

Purpose Although advances in Hodgkin lymphoma (HL) treatment have led to improved disease-free survival, this has been accompanied by an increased risk of second cancers. We sought to quantify the second cancer risks and to investigate the impact of family history. Patients and Methods Using the Swedish Family-Cancer Project Database, we identified 9,522 individuals with primary HL diagnosed between 1965 and 2012. We calculated standardized incidence ratios and cumulative incidence of second cancer in HL survivors and compared the standardized incidence ratios of lung, breast, colorectal, and

APA, Harvard, Vancouver, ISO, and other styles

23

McDonnell, Shannon K., Daniel J. Schaid, Jeffrey L. Myers, et al. "Efficacy of Contralateral Prophylactic Mastectomy in Women With a Personal and Family History of Breast Cancer." Journal of Clinical Oncology 19, no. 19 (2001): 3938–43. http://dx.doi.org/10.1200/jco.2001.19.19.3938.

Full text

Abstract:

PURPOSE: To estimate the efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. PATIENTS AND METHODS: We followed the course of 745 women with a first breast cancer and a family history of breast and/or ovarian cancer who underwent contralateral prophylactic mastectomy at the Mayo Clinic between 1960 and 1993. Family history information and cancer follow-up information were obtained from the medical record, a study-specific questionnaire, and telephone follow-up. Life-tables for contralateral breast cancers, which consider age at first b

APA, Harvard, Vancouver, ISO, and other styles

24

Ariga, Shin. "History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer." Journal of Clinical Medicine 12, no. 10 (2023): 3391. http://dx.doi.org/10.3390/jcm12103391.

Full text

Abstract:

Human epidermal growth factor receptor 2 (HER2) is a receptor tyrosine kinase that belongs to the human epidermal growth factor receptor family. It is overexpressed/amplified in approximately 20% of gastric or gastroesophageal junction cancers. HER2 is being developed as a therapeutic target in a variety of cancers, and several agents have been shown to be effective in breast cancer. The development of HER2-targeted therapy for gastric cancer successfully began with trastuzumab. However, while effective in breast cancer, the successive anti-HER2 agents lapatinib, T-DM1, and pertuzumab failed t

APA, Harvard, Vancouver, ISO, and other styles

25

MARUYAMA, A., T. SAITO, Y. HACHITANDA, and N. TSUKAMOTO. "Cancer history and loss of MSH2 and MLH1 protein expression in patients with endometrial hyperplasia." International Journal of Gynecologic Cancer 13, no. 3 (2003): 352–60. http://dx.doi.org/10.1136/ijgc-00009577-200305000-00015.

Full text

Abstract:

In order to evaluate the hereditary background of endometrial hyperplasia patients in relation to protein expression of DNA mismatch repair genes, we evaluated 69 patients with endometrial hyperplasia and 18 patients with normal endometrium having both a personal and family history of cancer (two hereditary nonpolypoid colorectal cancer (HNPCC) patients). We obtained personal and family histories of cancer for all patients. MSH2 and MLH1 protein expression was investigated by immunohistochemical methods. In the endometrial hyperplasia patients, 11 had personal histories and 40 had family histo

APA, Harvard, Vancouver, ISO, and other styles

26

Huang, Kai-Ling, Yu-Ling Liu, Ya-Ying Hsu, and Wen-Ling Kuo. "Retrospective Analysis of Clinicopathological Features and Familial Cancer History of Synchronous Bilateral Breast Cancer." Healthcare 9, no. 9 (2021): 1203. http://dx.doi.org/10.3390/healthcare9091203.

Full text

Abstract:

Bilateral breast cancer is a strong predictor of BRCA 1/2 mutation and hence one criterion indicated for hereditary genetic testing. The purpose of this study is to assess the characteristics of synchronous bilateral breast cancer (SBBC) and its association with personal and familial cancer traits. Patients diagnosed with SBBC in our institute between 1992 and 2018 were retrospectively reviewed, and the information of clinicopathological features, personal and family cancer history were analyzed. Of the 307 SBBCs enrolled, the growing case number generally aligned with the regional breast canc

APA, Harvard, Vancouver, ISO, and other styles

27

Yakushevskaya, O. V., V. G. Averkova, and S. V. Yureneva. "History of cancer and induced menopause: Help – cannot be reconciled." Meditsinskiy sovet = Medical Council, no. 4 (April 26, 2025): 151–59. https://doi.org/10.21518/ms2025-169.

Full text

Abstract:

Approximately one in five men or women develops some form of malignant neoplasm (MN) in their lifetimes. Around one in nine men and one in 12 women die from cancer. Ten major types of cancer comprise two-thirds of all new cases of cancer. Now, we can witness a change from impersonal treatment efficacy assessment to a personalized approach, including an analysis of cancer patient’s QoL, his/her age, comorbidity, stage, and immunohistochemical and molecular genetic characteristics of the tumour process. Despite revolutionary advancements in understanding of the molecular biology of tumours, inno

APA, Harvard, Vancouver, ISO, and other styles

28

Choi, Jin Ho, Woo Hyun Paik, Dong Kee Jang, et al. "Acute Pancreatitis Increases the Risk of Gastrointestinal Cancer in Type 2 Diabetic Patients: A Korean Nationwide Cohort Study." Cancers 14, no. 22 (2022): 5696. http://dx.doi.org/10.3390/cancers14225696.

Full text

Abstract:

The association between acute pancreatitis (AP) and gastrointestinal cancers in diabetic patients is currently not well understood. The study aim was to investigate the association between AP and gastrointestinal cancers in diabetic patients. Data from the Korean National Health Insurance Service database were analyzed. Participants with diabetes who underwent a health examination between 2009 and 2012 were followed up till December 2018. The primary outcome was the occurrence of gastrointestinal cancer. A total of 2,263,184 patients were included in the final analysis. Patients with a history

APA, Harvard, Vancouver, ISO, and other styles

29

Horinouchi, Hidehito, and Yuichiro Ohe. "History of Japan Clinical Oncology Group (JCOG) Lung Cancer Study Group." Japanese Journal of Clinical Oncology 50, no. 5 (2020): 502–11. http://dx.doi.org/10.1093/jjco/hyaa031.

Full text

Abstract:

Abstract The Japan Clinical Oncology Group Lung Cancer Study Group has been carrying out clinical studies, exploring new strategies of treatment, supportive therapies (antiemetics, etc.), etc., for a variety of cancers, including not only small cell lung cancer and non-small cell lung cancer but also rare chest tumours (represented by thymoma) and cancer-associated conditions (cancerous pericarditis, cancerous pleuritis, etc.). In this review, an overview of all studies conducted from 1985 to 2019 is provided.

APA, Harvard, Vancouver, ISO, and other styles

30

Cook, Linda S., Harold E. Nelson, Christine A. Stidley, et al. "Endometrial cancer and a family history of cancer." Gynecologic Oncology 130, no. 2 (2013): 334–39. http://dx.doi.org/10.1016/j.ygyno.2013.04.053.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Foschi, Roberto, Ersilia Lucenteforte, Cristina Bosetti, et al. "Family history of cancer and stomach cancer risk." International Journal of Cancer 123, no. 6 (2008): 1429–32. http://dx.doi.org/10.1002/ijc.23688.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Pinar, Gul, and Ali Ayhan. "Carcinomas Associated With Lynch Syndrome: A Family History." International Surgery 96, no. 4 (2011): 286–90. http://dx.doi.org/10.9738/cc15.1.

Full text

Abstract:

Abstract Lynch syndrome is a rare and inherited defect disorder. People who have Lynch syndrome are strongly predisposed to develop colorectal cancer as well as several other types of cancer. The aim of this study was to explore features of ovarian cancers arising in families with Lynch syndrome. This study was a case report based on family history examining three patients with a new diagnosis of colorectal adenocarcinoma with ovarian cancer. Family members of carriers of the mutations were counseled, and those found to be at risk were offered mutation testing. The clinical criteria of the Ams

APA, Harvard, Vancouver, ISO, and other styles

33

Huszno, Joanna, Magdalena Mazur, Elzbieta Nowara, and Ewa Grzybowska. "CHEK2 mutation in renal cell carcinoma (RCC): Single center experience." Journal of Clinical Oncology 35, no. 6_suppl (2017): 480. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.480.

Full text

Abstract:

480 Background: Renal cell cancer (RCC) accounts for about 4% of all the adult malignancies. RCC occurs in both sporadic and heritable forms. Genetic mutations have been identified as the cause of inherited cancer risk in 1% to 2% of RCC cases overall. In some studies, variant I157T of CHEK2 gene were found to be associated with increased risk of clear cell renal cancer. The aim of this study was to evaluate the association between CHEK2 mutation and RCC in our centre. Methods: We reviewed the medical records of 43 clear cell renal cancer patients (pts) who were diagnosed and treated in COI in

APA, Harvard, Vancouver, ISO, and other styles

34

Moon, Chulso, Maxie Gordon, David Moon, and Thomas Reynolds. "Microsatellite Instability Analysis (MSA) for Bladder Cancer: Past History and Future Directions." International Journal of Molecular Sciences 22, no. 23 (2021): 12864. http://dx.doi.org/10.3390/ijms222312864.

Full text

Abstract:

Microsatellite instability (MSI), the spontaneous loss or gain of nucleotides from repetitive DNA tracts, is a diagnostic phenotype for gastrointestinal, endometrial, colorectal, and bladder cancers; yet a landscape of instability events across a wider variety of cancer types is beginning to be discovered. The epigenetic inactivation of the MLH1 gene is often associated with sporadic MSI cancers. Recent next-generation sequencing (NGS)-based analyses have comprehensively characterized MSI-positive (MSI+) cancers, and several approaches to the detection of the MSI phenotype of tumors using NGS

APA, Harvard, Vancouver, ISO, and other styles

35

Ofner, Heidemarie, Gero Kramer, Shahrokh F. Shariat, and Melanie R. Hassler. "TP53 Deficiency in the Natural History of Prostate Cancer." Cancers 17, no. 4 (2025): 645. https://doi.org/10.3390/cancers17040645.

Full text

Abstract:

Prostate cancer remains a leading cause of cancer-related mortality in men, with advanced stages posing significant treatment challenges due to high morbidity and mortality. Among genetic alterations, TP53 mutations are among the most prevalent in cancers and are strongly associated with poor clinical outcomes and therapeutic resistance. This review investigates the role of TP53 mutations in prostate cancer progression, prognosis, and therapeutic development. A comprehensive analysis of preclinical and clinical studies was conducted to elucidate the molecular mechanisms, clinical implications,

APA, Harvard, Vancouver, ISO, and other styles

36

Topi, Skender, Luigi Santacroce, Lucrezia Bottalico, et al. "Gastric Cancer in History: A Perspective Interdisciplinary Study." Cancers 12, no. 2 (2020): 264. http://dx.doi.org/10.3390/cancers12020264.

Full text

Abstract:

Background: Gastric adenocarcinoma is the fourth most common type of cancer and the second leading cause of cancer death in the world. Despite abundant traces of an ancient history, the comprehension of its pathogenic mechanisms is rather recent and continuously updated. Methods: We investigated about how the ancient civilizations tried to understand the exactly physiopathology of gastric cancer, from the time when they could not examine deeply the histological and pathophysiologic aspects of the disease, but they just based their knowledge on a visual analysis of the signs and consequences of

APA, Harvard, Vancouver, ISO, and other styles

37

Hans, Stéphane, Robin Baudouin, Marta P. Circiu, et al. "Open Partial Laryngectomies: History of Laryngeal Cancer Surgery." Journal of Clinical Medicine 11, no. 18 (2022): 5352. http://dx.doi.org/10.3390/jcm11185352.

Full text

Abstract:

Historically, surgery was the first-choice therapy for early, intermediate and advanced laryngeal squamous cell carcinoma (LSCC). Partial laryngeal surgery has evolved in recent decades and was influenced by many historic events and the development of new technologies. Partial laryngectomies may be performed by open, endoscopic or transoral robotic approaches. In this historic paper, we describe the evolution of open partial laryngectomy techniques, indications and surgical outcomes. Since the first partial laryngectomy in 1788, many U.S., U.K. and European surgeons, including Henry Sands, Jac

APA, Harvard, Vancouver, ISO, and other styles

38

Sigua, B. V., V. P. Zemlyanoy, E. L. Lataria, E. A. Zakharov, S. Yu Rakita, and K. A. Lee. "History of pancreatic cancer surgery." Bulletin of the Russian Military Medical Academy 22, no. 3 (2020): 206–10. http://dx.doi.org/10.17816/brmma50561.

Full text

Abstract:

Abstract. The first mention of pancreatic cancer dates back to 1761, when the six-volume work of the famous Italian anatomist G. Morgagni On the location and causes of diseases discovered through dissection was published. However, the history of surgical treatment of malignant tumors of the pancreas dates back to the end of the 19th century. The accumulated experience of operational techniques and the introduction of aseptic rules created objective prerequisites for performing operations in complex anatomical zones during that period of time. On July 16, 1882, the famous German surgeon F. Tren

APA, Harvard, Vancouver, ISO, and other styles

39

Pontén, J. "Natural History of Breast Cancer." Acta Oncologica 29, no. 3 (1990): 325–29. http://dx.doi.org/10.3109/02841869009090008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Morrison, W. B. "Cancer Chemotherapy: An Annotated History." Journal of Veterinary Internal Medicine 24, no. 6 (2010): 1249–62. http://dx.doi.org/10.1111/j.1939-1676.2010.0590.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Jatoi, Ismail, William F. Anderson, Anthony B. Miller, and Otis W. Brawley. "The history of cancer screening." Current Problems in Surgery 56, no. 4 (2019): 138–63. http://dx.doi.org/10.1067/j.cpsurg.2018.12.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

DeVita, Vincent T., and Edward Chu. "A History of Cancer Chemotherapy." Cancer Research 68, no. 21 (2008): 8643–53. http://dx.doi.org/10.1158/0008-5472.can-07-6611.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Carroll, J. C., R. Heisey, and E. Warner. "Family history and breast cancer." Canadian Medical Association Journal 184, no. 12 (2012): 1391. http://dx.doi.org/10.1503/cmaj.111670.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Niv, Yaron. "Family History of Gastric Cancer." Journal of Clinical Gastroenterology 36, no. 3 (2003): 204–8. http://dx.doi.org/10.1097/00004836-200303000-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Feinberg, Andrew P., and Benjamin Tycko. "The history of cancer epigenetics." Nature Reviews Cancer 4, no. 2 (2004): 143–53. http://dx.doi.org/10.1038/nrc1279.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Cook, Jackie. "Family history of ovarian cancer." Current Obstetrics & Gynaecology 12, no. 1 (2002): 47–51. http://dx.doi.org/10.1054/cuog.2001.0232.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Kelly, Patricia Paul. "Colorectal Cancer Family History Assessment." Clinical Journal of Oncology Nursing 15, no. 5 (2011): E75—E82. http://dx.doi.org/10.1188/11.cjon.e75-e82.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Winawer, Sidney J. "Natural history of colorectal cancer." American Journal of Medicine 106, no. 1 (1999): 3–6. http://dx.doi.org/10.1016/s0002-9343(98)00338-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Sriprasad, Seshadri, Mark R. Feneley, and Peter M. Thompson. "History of prostate cancer treatment." Surgical Oncology 18, no. 3 (2009): 185–91. http://dx.doi.org/10.1016/j.suronc.2009.07.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Keku, Temitope O., Robert C. Millikan, Chris Martin, Tejinder K. Rahkra-Burris, and Robert S. Sandler. "Family history of colon cancer." American Journal of Preventive Medicine 24, no. 2 (2003): 170–76. http://dx.doi.org/10.1016/s0749-3797(02)00590-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!